Homechevron_rightAll Peptideschevron_rightKLOW Blend Injection Pen

verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-klow-peptide-blend-injection-pen-80mg

Official Product Data Sheet

KLOW Blend Injection Pen (80mg)

High >98% Purity

Vial Contents

80 mg KLOW blend (TB-500 10mg + BPC-157 10mg + KPV 10mg + GHK-Cu 50mg) — 3 mL pre-filled injection pen

Includes

Ready-to-use multi-dose injection pen — no mixing or reconstitution required

Form

Pre-filled multi-dose peptide blend pen

Purity

≥98%, third-party verified

Sequence

TB-500 10mg + BPC-157 10mg + KPV 10mg + GHK-Cu 50mg

Molecular Formula

See chemical properties

Molecular Mass

N/A

CAS No.

N/A

Solubility

Concentration: ≈26.67 mg/mL total | Per click: 1 unit ≈ TB-500 33.3mcg, BPC-157 33.3mcg, KPV 33.3mcg, GHK-Cu 16.7mcg

Storage

Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new

View all authorized resellersshopping_cart

swipe_rightSwipe to see all tabs

Scientific Background

KLOW Blend is a research-focused multi-peptide formulation containing TB-500, BPC-157, KPV, and GHK-Cu, designed to target tissue repair, inflammation reduction, and skin rejuvenation through four complementary mechanisms. TB-500 promotes cell migration and angiogenesis, BPC-157 enhances localized repair and growth factor signaling, KPV dampens pro-inflammatory cytokines through NF-κB modulation, and GHK-Cu boosts collagen synthesis and antioxidant defenses. Delivered in a single daily pen, KLOW eliminates the complexity of multi-vial protocols.

Intended Research Use

Multi-pathway tissue repair and regeneration research
KPV-mediated cytokine modulation and inflammation control studies
Angiogenesis and cell migration research (TB-500)
Collagen synthesis and skin rejuvenation investigations (GHK-Cu)
BPC-157 localized repair and growth factor pathway studies

menu_bookScientific Publications

article

Expert Opin Biol Ther (2012)

Thymosin β4: a multi-functional regenerative peptide

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/22074294/

article

J Appl Physiol (2011)

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/21030672/

article

Gastroenterology (2008)

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/18061177/

article

Int J Mol Sci (2018)

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/29986520/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

KLOW's four-peptide blend pairs well with additional targeted peptides for intensified research into specific regenerative pathways.

GHK-Cu 50mg (50mg vial)

arrow_forward

myo-ghk-cu-50mg

Intensified skin repair and collagen focus — additional GHK-Cu for deeper cellular rejuvenation and antioxidant research alongside the KLOW blend.

TB-500 5mg (5mg vial)

arrow_forward

myo-tb-500-5mg

Amplified angiogenesis and systemic recovery — additional TB-500 vial for targeted administration alongside the multi-pathway KLOW blend.

ARA-290 10mg (10mg vial)

arrow_forward

myo-ara-290-10mg

Added neuroprotective and anti-inflammatory synergy — ARA-290's erythropoietin receptor activation complements KPV's cytokine modulation for comprehensive tissue defense research.

schedule

Cycling Note: Typical protocol: 8–12 weeks. At 15 units/day, one 80 mg pen lasts approximately 20 days.

Also Available

Vial

KLOW Blend

80mg